We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+41.47%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$4.2B
AUM Growth
+$1.6B
Cap. Flow
+$825M
Cap. Flow %
19.63%
Top 10 Hldgs %
44.15%
Holding
117
New
24
Increased
10
Reduced
49
Closed
12

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$207M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$150M
3
BCAB icon
BioAtla
BCAB
+$76.6M
4
CCCC icon
C4 Therapeutics
CCCC
+$72.2M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$48.8M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$61.3M
2
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$50.2M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$35.5M
4
TWST icon
Twist Bioscience
TWST
+$30.5M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 78.9%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALBO
51
DELISTED
Albireo Pharma Inc
ALBO
$18.8M 0.45%
500,000
-200,000
-29% -$7.27M
OTIC
52
DELISTED
Otonomy, Inc.
OTIC
$16.8M 0.4%
2,600,000
-641,800
-20% -$2.92M
ASND icon
53
Ascendis Pharma A/S
ASND
$16.8B
$16.7M 0.4%
100,000
-25,000
-20% -$4.13M
NTLA icon
54
PUT
Intellia Therapeutics
NTLA
$1.67B
$16.3M 0.39%
+300,000
New +$10.9M
AXSM icon
55
Axsome Therapeutics
AXSM
$10.9B
$16.3M 0.39%
200,000
-50,000
-20% -$3.74M
TCRR
56
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$15.5M 0.37%
500,000
-100,000
-17% -$2.53M
OMER icon
57
CALL
Omeros
OMER
$959M
$14.3M 0.34%
1,000,000
– –
ANAB icon
58
AnaptysBio
ANAB
$1.68B
$14M 0.33%
650,000
– –
PLRX icon
59
Pliant Therapeutics
PLRX
$65M
$13.9M 0.33%
611,409
– –
SRPT icon
60
Sarepta Therapeutics
SRPT
$1.77B
$11.9M 0.28%
70,000
-15,000
-18% -$2.22M
DCPH
61
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$11.4M 0.27%
200,000
-50,000
-20% -$2.96M
RPTX
62
DELISTED
Repare Therapeutics
RPTX
$10.3M 0.24%
300,000
-48,567
-14% -$1.45M
OBIO icon
63
Orchestra BioMed
OBIO
$254M
$10.2M 0.24%
800,000
– –
ITOS
64
DELISTED
iTeos Therapeutics
ITOS
$10.1M 0.24%
300,000
-50,000
-14% -$1.32M
INSM icon
65
Insmed
INSM
$28.6B
$9.99M 0.24%
300,000
-50,000
-14% -$1.83M
AKUS
66
DELISTED
Akouos Inc
AKUS
$9.91M 0.24%
499,990
-1
-0% -$19
TBPH icon
67
Theravance Biopharma
TBPH
$877M
$9.77M 0.23%
550,000
-100,072
-15% -$1.8M
HARP
68
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$9.48M 0.23%
57,060
– –
TNGX icon
69
Tango Therapeutics
TNGX
$4.41B
$9.15M 0.22%
800,000
– –
SWTX
70
DELISTED
SpringWorks Therapeutics
SWTX
$9.06M 0.22%
+125,000
New +$8.05M
QURE icon
71
uniQure
QURE
$3.22B
$9.03M 0.21%
250,000
-75,000
-23% -$3.16M
ARGX icon
72
argenx
ARGX
$54.1B
$8.82M 0.21%
30,000
-10,000
-25% -$2.75M
TARA icon
73
Protara Therapeutics
TARA
$232M
$8.47M 0.2%
350,000
-100,000
-22% -$2.16M
FDMT icon
74
4D Molecular Therapeutics
FDMT
$562M
$8.29M 0.2%
+200,000
New +$8.26M
GOSS icon
75
Gossamer Bio
GOSS
$87M
$8.2M 0.2%
848,382
+600,000
+242% +$5.91M
1 2
3
4 5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2020 Portfolio in Review

As of Q4 2020, Cormorant Asset Management held 117 positions worth $4.2B, up 62% from $2.6B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management deployed $825M of net new capital in Q4 2020, opening 24 new positions and adding to 10 existing holdings. Its largest new stake was Atea Pharmaceuticals: 6,411,355 shares worth $260M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Twist Bioscience, an estimated $30.5M trimmed.

  • Cormorant Asset Management's largest Q4 2020 buy was Atea Pharmaceuticals: 6,411,355 shares worth $260M.
  • Cormorant Asset Management added most to Forma Therapeutics Holdings, Inc. Common Stock in Q4 2020, an estimated $47M increase.
  • Cormorant Asset Management's biggest Q4 2020 reduction was Twist Bioscience, cutting an estimated $30.5M.
  • Cormorant Asset Management fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $61.3M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $4.2B portfolio in Q4 2020.
  • Cormorant Asset Management opened 24 new positions and closed 12 in Q4 2020.
  • Cormorant Asset Management's portfolio value rose 62% quarter-over-quarter to $4.2B.

Based on Cormorant Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.